BioSpace News Archive

Genetown

Less than 18 Months After Launch, Ohana Biosciences Closes Its Doors

Launched in January 2020 by Flagship Pioneering, Ohana was being dubbed a “first-in-category reproductive health company” focused on the industry’s first sperm biology platform.

April 28, 2021
·
3 min read
·
Mark Terry
Policy

FDA Issues CRL for Protalix and Chiesi’s Fabry Disease Drug

The companies indicated they are studying the CRL to determine the best way to understand the problems and what course of action they might take.

April 28, 2021
·
2 min read
·
Mark Terry
Drug Development

Pfizer Expands Presence in Antimicrobials with Amplyx Acquisition

Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.

April 28, 2021
·
2 min read
·
Alex Keown
Job Trends

Novartis CEO Says Remote Work Hybrid Should Mean Access to New Talent Pools

Novartis AG Chief Executive Officer Vas Narasimhan believes that the hybrid of remote and on-site office work is the future.

April 28, 2021
·
3 min read
·
Ava Barnes
CPhI Japan celebrates return, as cell & gene therapies and digital innovation highlighted

CPhI Japan, the first large pharma event to trade in 2021, played host to 7214 attendees at the exhibition and a further 7204 virtual users from across the globe.

April 28, 2021
·
5 min read
FDA

Takeda Closes in on Potential Approval for NSCLC Drug, Mobocertinib

Takeda’s non-small cell lung cancer treatment Mobocertinib is leading closer to regulatory approval after the U.S. Food and Drug Administration granted priority review to the New Drug Application.

April 28, 2021
·
2 min read
·
Alex Keown
Business

Developing ‘Antennae’ for Drug Regulation and Policy: A Conversation with Geoffrey Levitt

Levitt has practiced law for over 20 years in the FDA regulatory space. Previously chief regulatory counsel for Pfizer Inc., Levitt has had extensive experience working with an interdisciplinary team of scientists, executives and lawyers to push a candidate to market.

April 28, 2021
·
5 min read
·
Maggie Chen
Biotech Beach

Cutting-Edge Biotechs Raise Investors’ Hopes: Exscientia and Boundless Bio

Investors are still hungry for cutting-edge biotech companies that can make a difference in people’s lives with the hope of a big return on investment. Here’s a look at two recent big funding rounds.

April 28, 2021
·
4 min read
·
Mark Terry
Business

Biotech Tilts at the Tipping Point of Gender Equality

A recent report by Deerfield Management Company revealed an unsettling but unsurprising truth: There is a significant gender gap on the boards of venture-backed healthcare companies.

April 28, 2021
·
5 min read
·
Heather McKenzie
Biotech Bay

Preparing a Pandemic Plan for Whatever Comes Our Way Next

According to Teo, the definition of the next pandemic depends a lot on one’s perspective.

April 28, 2021
·
7 min read
·
Heather McKenzie